New antibody combo tested in advanced cancer patients
NCT ID NCT05025085
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Because it is a phase 1 study, it is too early to know if the drug works well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGEN1777 (an antibody) and a PD-1 inhibitor (another antibody)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 25 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is far from being proven effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Local Institution - 0001
Providence, Rhode Island, 02903, United States
-
Local Institution - 024
Southfield, Michigan, 48075, United States
-
Local Institution - 072
Cincinnati, Ohio, 45267-0558, United States
-
Local Institution - 164
Dallas, Texas, 75230, United States
-
Local Institution - 165
Grand Rapids, Michigan, 49546, United States
-
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
University of Cincinnati Cancer Center
Cincinnati, Ohio, 45267, United States